|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
N6-Isopentenyladenosine Inhibits Colorectal Cancer and Improves Sensitivity to 5-Fluorouracil-Targeting FBXW7 Tumor Suppressor.
|
31569395 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Clinically, miR-92a-3p expression is significantly increased in CRC tissues and negatively correlated with the levels of FBXW7 and MOAP1 in CRC specimens, and high expression of exosomal miR-92a-3p in serum was highly linked with metastasis and chemotherapy resistance in CRC patients.
|
31064356 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
On contrast, circ-FBXW7 overexpressed significantly suppressed CRC cell proliferation, migration and invasion.
|
31519156 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results suggest that STYX plays an oncogenic role by inhibiting FBXW7 and represents a potential therapeutic target and prognostic biomarker in CRC.
|
30981757 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance.
|
30783098 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The proportion of FBXW7-positive cells in surgically resected CRC specimens from patients who underwent NAC or NACRT was significantly higher than that in the pre-treatment biopsy specimens (<i>p</i> < 0.001).
|
31067777 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
FBW7 has been reported to be one of the most frequently mutated genes in colorectal cancer (CRC).
|
29910683 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The deubiquitinase USP9X regulates FBW7 stability and suppresses colorectal cancer.
|
29346117 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, miR-223/FBXW7 axis regulates doxorubicin sensitivity through EMT in CRC, which may lead to the development of individualized treatment in clinical practice.
|
29701752 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, Fbw7 loss increases the susceptibility of colorectal cancer.
|
29550488 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, these findings suggest that ZNF746 promotes CRC progression via c-Myc stability mediated by GSK3 and FBW7.
|
29628506 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRC cells containing FBW7-inactivating mutations are insensitive to clinically used multi-kinase inhibitors of RAS/RAF/MEK/ERK signaling, including regorafenib and sorafenib.
|
27399335 |
2017 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The FBXW7 over-expression was further validated in resected liver metastatic sites in CRC patients after chemotherapy.
|
28699179 |
2017 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
FBXW7 functions as a ubiquitin ligase tagging multiple dominant oncogenic proteins and commonly mutates in colorectal cancer.
|
28424412 |
2017 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, Plk2 binds to Fbxw7 and results in its subsequent degradation, which in turn leads to the stabilization of Cyclin E. The pro-tumor activity of Plk2 could be inverted by restoring Fbxw7 expression and depletion of Cyclin E. In addition, the expressions of Fbxw7 and Cyclin E were significantly associated with Plk2 protein levels in CRC tissues.
|
27423313 |
2016 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers.
|
27244218 |
2016 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings indicate that the upregulation of CRY2 caused by downregulation of FBXW7 may be a novel prognostic biomarker and may represent a new therapeutic target in colorectal cancer.
|
25855785 |
2015 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
|
25860929 |
2015 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
FBXW7 negatively regulates ENO1 expression and function in colorectal cancer.
|
26097998 |
2015 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients.
|
25450649 |
2015 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
FBXW7 encodes the substrate recognition component of a ubiquitin ligase that degrades targets such as Notch1, c-Jun, c-Myc and cyclin E. FBXW7 mutations occur in several tumour types, including colorectal cancers.
|
23676439 |
2014 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that Fbw7 and p53 synergistically suppress adenocarcinomas that mimic advanced human CRC with respect to histopathology, metastasis, and CIN.
|
22473991 |
2012 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Fbw7 is the fourth most frequently mutated gene in human colorectal carcinomas and has recently been described as a poor prognosis marker in human colorectal carcinoma; however, the molecular mechanism underlying fbw7 mutations in intestinal tumor suppression is unclear.
|
20638938 |
2010 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using CGH array, the copy number aberrations of the flanking region of FBXW7 were evaluated in another 130 CRC specimens.
|
19739118 |
2010 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability.
|
16357143 |
2005 |